Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 | O43525 | 4/20 | 0.36 |
| ▸ | KCNQ2 | O43526 | 4/20 | 0.36 |
| ▸ | PLAT | P00750 | 2/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.32 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | PDE2A | O00408 | 2/20 | 0.31 |
| ▸ | TACR1 | P25103 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | PTGES | O14684 | 1/20 | 0.31 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | PSD | A5PKW4 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
| ▸ | USP1 | O94782 | 1/20 | 0.30 |
| ▸ | WDR48 | Q8TAF3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15926314 | 0.91 | KCNQ3 (0.36) | KCNQ3KCNQ2TRPV1LMNAPOLB | |
| SCHEMBL1613466 | 0.87 | AR (0.40) | PLATPDE2ATACR1AR | |
| SCHEMBL1614735 | 0.83 | PLAT (0.33) | KCNQ3KCNQ2PLATPDE2AAR | |
| SCHEMBL1614661 | 0.82 | LMNA (0.36) | KCNQ3KCNQ2LMNAPOLBAURKA | |
| SCHEMBL15926362 | 0.80 | AR (0.37) | KCNQ3KCNQ2PLATPOLBPDE2A | |
| SCHEMBL1613995 | 0.79 | PDE2A (0.34) | PLATLMNAPDE2A | |
| SCHEMBL15909598 | 0.76 | LMNA (0.43) | KCNQ3KCNQ2TRPV1LMNAPOLB | |
| SCHEMBL15926318 | 0.76 | MAPK14 (0.32) | KCNQ3KCNQ2HCAR2 | |
| SCHEMBL1614666 | 0.75 | MAPT (0.33) | KCNQ3KCNQ2HCAR2 | |
| SCHEMBL1614820 | 0.74 | KCNQ3 (0.42) | KCNQ3KCNQ2PLATPSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8796285-B2 | Pyrazolo [1,5-a]-pyrimidones derivatives and pharmaceutical compositions and uses thereof | HEBEI MEDICAL UNIVERSITY (CN) | 2014-08-05 | — | — | US | disclosed |
| US-20120088775-A1 | Pyrazolo-[1,5-a]-Pyrimidones Derivatives and Pharmaceutical Compositions and Uses Thereof | PEKING UNIVERSITY (CN) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088775-A1 | Pyrazolo-[1,5-a]-Pyrimidones Derivatives and Pharmaceutical Compositions and Uses Thereof | KCNJ2, KCNQ5, KCNJ11 | KCNQ3 12/4885KCNQ2 9/4885PLAT 1286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.